# Evaluation of Surgical Removal of Pituitary Tumours By Trans-sphenoidal Approach

Thesis
Submitted For Partial Fulfilment of
M.Sc. (General Surgery)

By
Omar Yousef Omar Hammad
M.B., B.Ch.

## Supervisors Prof. Dr. Ahmed Samir El-Molla

Prof of Neurosurgery Faculty of Medicine Ain Shams University

#### Prof. Dr. Adel Hussein El-Hakim

Prof of Neurosurgery Faculty of Medicine Ain Shams University

#### Dr. Hossam El-Husseni


6.7.44

Lecturer of Neurosurgery Faculty of Medicine Ain Shams University

Faculty of Medicine Ain Shams University

1992





## Acknowledgments

My sincere gratitude should be submitted first to ALLAH, who always helps me and cares for me.

It is a great pleasure to express my sincere thanks and gratitude to **Prof. Dr. Ahmed Samir El-Molla**, Prof of Neurosurgery, Faculty of Medicine, Ain Shams University for his enthusiastic guidance, generous supervision and constructive criticism. All this and more, leaves me greatly indebted.


My great thanks for **Prof. Dr. Adel Hussein El-Hakim**, for his advice and continuous encouragement during the whole work.

I am deeply indebted to Dr. Hossam El-Huseini for precious guidance and valuable suggestions.

My great thanks to all my professors and colleagues for their generous advice and cooperation.

Lastly, I am greatly thankful to all who offered me any kind of help, especially my patients who gave me this chance to learn.






### **Contents**

☐ Introduction and aim of the work	1
• Surgical approaches  Trans-sphenoidal approach  Transcranial approach	3 6 15 23 32 48 54 62 62 69 75 77 82 88
☐ Illustrative cases	
□ Results	95
☐ Discussion	120
□ Conclusion	126
☐ Summary	127
☐ References	130
☐ Arabic summary	141

forms         19         3         formed           stomodeum         2         Fig.1         stomedium           shenoid         6         16         sphenoid           anterior cerebral         2         22         anterior communicating           β endophin         15         24         β endorphin           vosopressim         6         30         vasopressin           chondromas         12         33         chordomas           will         2         Fig.17         well           mommosomatotropic         17         36         mammosomatotropic           cel         19         36         cell           hyperprolactinemica         3         38         hyperprolactinemic           endorsphins         14         39         endorphins           proloctin         2         Fig-20         prolactin           orgonelles         2         Fig-21         organelles           hypopituitrism         19         44         hypopituitarism           cloumiphen         18         48         clomiphen           exception         19         50         except           carcinopharyngioma         14	Incorrect	Line	Page/Figure	Correct
stomodeum		19	3	
shenoid         6         16         sphenoid           anterior cerebral         2         22         anterior communicating           β endophin         15         24         β endorphin           vosopressim         6         30         vasopressin           chondromas         12         33         chordomas           will         2         Fig.17         well           mommosomatotropic         17         36         mammosomatotropic           cel         19         36         cell           hyperprolactinemica         3         38         hyperprolactinemic           endorsphins         14         39         endorphins           proloctin         2         Fig-20         prolactin           orgonelles         2         Fig-21         organelles           hypopituitrism         19         44         hypopituitarism           cloumiphen         18         48         clomiphen           exception         19         50         except           carcinopharyngioma         14         51         craniopharyngioma           Tindall, Barrow,         2,17         52         Tindall, Barrow, 199           et, a	stomodeum	2	Fig.1	
anterior cerebral         2         22         anterior comm-           1         unicating           β endophin         15         24         β endorphin           vosopressim         6         30         vasopressin           chondromas         12         33         chordomas           will         2         Fig.17         well           mommosomatotropic         17         36         mammosomatotropic           cel         19         36         cell           hyperprolactinemica         3         38         hyperprolactinemic           endorsphins         14         39         endorphins           proloctin         2         Fig-20         prolactin           orgonelles         2         Fig-21         organelles           hypopituitrism         19         44         hypopituitarism           cloumiphen         18         48         clomiphen           exception         19         50         except           carcinopharyngioma         14         51         craniopharyngioma           tal, 1990         Tindall, Barrow,         4         53         Tindall, Barrow, 199           et, al, 1990         Tin		6	16	
Sendophin   15   24   β endorphin	anterior cerebral	2	22	
Pendophin         15         24         β endorphin           vosopressim         6         30         vasopressin           chondromas         12         33         chordomas           will         2         Fig.17         well           mommosomatotropic         17         36         mammosomatotropic           cel         19         36         cell           hyperprolactinemica         3         38         hyperprolactinemic           endorsphins         14         39         endorphins           proloctin         2         Fig-20         prolactin           organelles         2         Fig-21         organelles           hypopituitrism         19         44         hypopituitarism           cloumiphen         18         48         clomiphen           exception         19         50         except           carcinopharyngioma         14         51         craniopharyngioma           Tindall, Barrow,         2,17         52         Tindall, Barrow, 199           et,al,1990         4         53         Tindall, Barrow, 199           exndocrine         4         52         endocrine           matyrapose<				
vosspressim         6         30         vasopressin           chondromas         12         33         chordomas           will         2         Fig.17         well           mommosomatotropic         17         36         mammosomatotropic           cel         19         36         cell           hyperprolactinemica         3         38         hyperprolactinemic           endorsphins         14         39         endorphins           proloctin         2         Fig-20         prolactin           organelles         2         Fig-21         organelles           hypopituitrism         19         44         hypopituitarism           cloumiphen         18         48         clomiphen           exception         19         50         except           carcinopharyngioma         14         51         craniopharyngioma           Tindall, Barrow,         2,17         52         Tindall, Barrow, 199           et,al,1990         Tindall, Barrow,         19         53         Tindall, Barrow, 199           exndocrine         4         52         endocrine           matyrapose         20         53         metyrapone <td><b>B</b> endophin</td> <td>15</td> <td>24</td> <td></td>	<b>B</b> endophin	15	24	
chondromas         12         33         chordomas           will         2         Fig.17         well           mommosomatotropic         17         36         mammosomatotropic           cel         19         36         cell           hyperprolactinemica         3         38         hyperprolactinemic           endorsphins         14         39         endorphins           proloctin         2         Fig-20         prolactin           organelles         2         Fig-21         organelles           hypopituitrism         19         44         hypopituitarism           cloumiphen         18         48         clomiphen           exception         19         50         except           carcinopharyngioma         14         51         craniopharyngioma           Tindall, Barrow,         2,17         52         Tindall, Barrow, 199           et,al,1990         Tindall, Barrow,         4         53         Tindall, Barrow, 199           exndocrine         4         52         endocrine           matyrapose         20         53         metyrapone           vinous         11         57         venous	vosopressim	6	30	
will         2         Fig.17         well           mommosomatotropic         17         36         mammosomatotropic           cel         19         36         cell           hyperprolactinemica         3         38         hyperprolactinemic           endorsphins         14         39         endorphins           proloctin         2         Fig-20         prolactin           organelles         2         Fig-21         organelles           hypopituitrism         19         44         hypopituitarism           cloumiphen         18         48         clomiphen           exception         19         50         except           carcinopharyngioma         14         51         craniopharyngioma           Tindall, Barrow,         2,17         52         Tindall, Barrow, 199           et,al,1990         exndocrine         4         53         Tindall, Barrow, 199           exndocrine         4         52         endocrine           matyrapose         20         53         metyrapone           vinous         11         57         venous	chondromas	12	33	
mommosomatotropic 17 36 mammosomatotropic cel 19 36 cell hyperprolactinemica 3 38 hyperprolactinemi endorsphins 14 39 endorphins proloctin 2 Fig-20 prolactin organelles 2 Fig-21 organelles hypopituitrism 19 44 hypopituitarism cloumiphen 18 48 clomiphen exception 19 50 except carcinopharyngioma 14 51 craniopharyngioma 14 51 craniopharyngioma Tindall, Barrow, 2,17 52 Tindall, Barrow, 199 et, al, 1990 exndocrine 4 52 endocrine matyrapose 20 53 metyrapone vinous 11 57 venous	will	2	Fig.17	
hyperprolactinemica 3 38 hyperprolactinemica and an endorsphins 14 39 endorphins proloctin 2 Fig-20 prolactin organelles 2 Fig-21 organelles hypopituitrism 19 44 hypopituitarism cloumiphen 18 48 clomiphen exception 19 50 except carcinopharyngioma 14 51 craniopharyngioma 14 51 craniopharyngioma 14 51 craniopharyngioma 14 51 rindall, Barrow, 2,17 52 Tindall, Barrow, 199 et,al,1990 exndocrine 4 52 endocrine matyrapose 20 53 metyrapone vinous 11 57 venous	mommosomatotropic	17		
hyperprolactinemica 3 38 hyperprolactinemic endorsphins 14 39 endorphins proloctin 2 Fig-20 prolactin organelles 2 Fig-21 organelles hypopituitrism 19 44 hypopituitarism cloumiphen 18 48 clomiphen exception 19 50 except carcinopharyngioma 14 51 craniopharyngioma Tindall, Barrow, 2,17 52 Tindall, Barrow, 199 et,al,1990  Tindall, Barrow, 4 53 Tindall, Barrow, 199 exandocrine 4 52 endocrine matyrapose 20 53 metyrapone vinous 11 57 venous	cel	19	36	
proloctin 2 Fig-20 prolactin organelles 2 Fig-21 organelles hypopituitrism 19 44 hypopituitarism cloumiphen 18 48 clomiphen exception 19 50 except carcinopharyngioma 14 51 craniopharyngioma Tindall, Barrow, 2,17 52 Tindall, Barrow, 1990 et,al,1990 et,al,1990 exndocrine 4 52 endocrine matyrapose 20 53 metyrapone vinous 11 57 venous investigations	hyperprolactinemica	<b>a</b> 3	38	
proloctin 2 Fig-20 prolactin orgonelles 2 Fig-21 organelles hypopituitrism 19 44 hypopituitarism cloumiphen 18 48 clomiphen exception 19 50 except carcinopharyngioma 14 51 craniopharyngioma Tindall, Barrow, 2,17 52 Tindall, Barrow, 199 et,al,1990 Tindall, Barrow, 4 53 Tindall, Barrow, 199 exndocrine 4 52 endocrine matyrapose 20 53 metyrapone vinous 11 57 venous	endorsphins	14	39	
orgonelles 2 Fig-21 organelles hypopituitrism 19 44 hypopituitarism cloumiphen 18 48 clomiphen exception 19 50 except carcinopharyngioma 14 51 craniopharyngioma Tindall, Barrow, 2,17 52 Tindall, Barrow, 199 et,al,1990 Tindall, Barrow, 4 53 Tindall, Barrow, 199 exndocrine 4 52 endocrine matyrapose 20 53 metyrapone vinous 11 57 venous	proloctin	2		
hypopituitrism 19 44 hypopituitarism cloumiphen 18 48 clomiphen exception 19 50 except carcinopharyngioma 14 51 craniopharyngioma Tindall, Barrow, 2,17 52 Tindall, Barrow, 199 et, al, 1990  Tindall, Barrow, 4 53 Tindall, Barrow, 199 exadocrine 4 52 endocrine matyrapose 20 53 metyrapone vinous 11 57 venous	orgonelles	2		
cloumiphen 18 48 clomiphen exception 19 50 except carcinopharyngioma 14 51 craniopharyngioma Tindall, Barrow, 2,17 52 Tindall, Barrow, 199 et,al,1990 Tindall, Barrow, 4 53 Tindall, Barrow, 199 et,al,1990 exndocrine 4 52 endocrine matyrapose 20 53 metyrapone vinous 11 57 venous	hypopituitrism	19	-	
exception 19 50 except  carcinopharyngioma 14 51 craniopharyngioma  Tindall, Barrow, 2,17 52 Tindall, Barrow, 199  et,al,1990  Tindall, Barrow, 4 53 Tindall, Barrow, 199  et,al,1990  exndocrine 4 52 endocrine  matyrapose 20 53 metyrapone  vinous 11 57 venous	cloumiphen	18	- <del>-</del>	
carcinopharyngioma 14 51 craniopharyngioma Tindall, Barrow, 2,17 52 Tindall, Barrow, 199 et,al,1990 Tindall, Barrow, 4 53 Tindall, Barrow, 199 et,al,1990 exndocrine 4 52 endocrine matyrapose 20 53 metyrapone vinous 11 57 venous	exception	19		
Tindall, Barrow, 2,17 52 Tindall, Barrow, 199 et,al,1990 Tindall, Barrow, 4 53 Tindall, Barrow, 199 et,al,1990 exndocrine 4 52 endocrine matyrapose 20 53 metyrapone vinous 11 57 venous	carcinopharyngioma	14	_	
et,al,1990  Tindall,Barrow,199  Et,al,1990  et,al,1990  exndocrine  matyrapose  vinous  investigations	Tindall,Barrow,	2.17		
et,al,1990  exndocrine  4  52  endocrine  matyrapose  20  53  metyrapone  investigations	et,al,1990	, .	J.Z.	Tindall, Barrow, 1990
et,al,1990  exndocrine  4  52  endocrine  matyrapose  20  53  metyrapone  investigations	Tindall, Barrow,	4	53	
matyrapose 20 53 metyrapone vinous 11 57 venous			33	Tindall,Barrow,1990
matyrapose 20 53 metyrapone vinous 11 57 venous	exndocrine	4	5.2	
vinous 11 57 wenous investigations 10	matyrapose			
investigations 10 venous	vinous			
58 investigators	investigatiors	19		

Incorrect	Line	Page/Fig	Correct
acrommegalic	1	Fig. 29	acromegalic
chondromas	13	60	chordomas
patians	12	130	patients
collegue	1	65	colleagues
Wilsonm	11	68	Wilson
pituitry	20	138	pituitary
pituitry	11	136	pituitary
responce	1,4	71	response
cushing	7	72	cushing's
recurence	14	72	recurrence
Halbeig	20	72	Halberg
sphonoid	2	Fig. 36	sphenoid
retrochiasmtic	12,17	82	retrochiasmatic
striotactic	20	137	stereotactic
striotactic	1	88	stereotactic

Incorrect	Line	Page/Fig	Correct
180°C	7	88	-180°C
hyperprolactinemi	18	92	hyperprolactinemia
protein	10	93	prolactin
primarily	7	103	primary
behaviours	18	106	behaviour
cases	12	118	case
hydrocephalus	14	123,127	hydrocephelus
They were	5	124	5 cases were
incipidus	4	128	insipidus
Trans-spenoidl	1	134	trans-sphenoidal



#### Introduction & Aim of The Work


Pituitary adenomas are frequently occurring epithelial neoplasms composed of and deriving from adenohypophyseal cells. They represent approximately 10% of intracranial tumours. In the majority of cases, they are benign and slow growing. However, some tumours exhibit a more rapid growth rate and invade the surrounding structures.

Pituitary adenomas are either secreting adenomas or nonfunctioning adenomas. The secreting adenomas produce hormonal disturbances which is reflected on the physiological functions of the body. The nonfunctioning adenomas presented by mass effect with chiasmal compression and subsequent visual troubles.

The goals of surgical intervention in pituitary adenomas are to remove the tumour, relief chiasmal compression and correction of endocrinopathy. While the surgical management of pituitary adenomas continues to be a safe and effective method for dealing with a large number of these lesions, the trans-sphenoidal approach had proved to be more physiologic, more tolerated and safer than the cranial approach. Among the different routes to

the sphenoid, the trans-septal route is the most direct, atraumatic and easiest of all of them. Our experience in the trans-septal approach for treating patients with pituitary adenomas of different types and sizes is discussed.

Introduction & Aim of The Work



#### **I-Embryology**

The human pituitary gland is divided into two lobes, the anterior lobe or adenohypophysis and the posterior lobe or neurohypophysis. Although each has a distinct embryological origin, the two lobes become intimately related during embryogenesis and remain so (Tindall and Barrow, 1990).

Between the third and fourth weeks of embryonic development, a longitudinal groove, "the sulcus limitans" appears in the lumen of the neural tube. This sulcus divides the alar (dorsal) plate from the basal (ventral) plate. The basal plate plays no part in the development of the hypothalamus or pituitary, participating only in the formation of nervous tissue caudal to the diencephalon. At about five and a half weeks the alar plate in the region that gives rise to the diencephalon, develops a longitudinal groove contiguous with the sulcus limitans, this groove the "hypothalamic sulcus" divides the alar plate into a dorsal portion that gives rise to thalamus and ventral portion that gives rise to the hypothalamus (Cooper and Martin, 1990).

During the fifth week of gestation, a midline diverticulum "Rathk's pouch" forms as an outgrowth of the primitive




Fig ( 1 ) Embryogenesis of pituitary gland. (A), Early invagination of primitive stomodeum and infundibular process. (B) Growth of mesoderm Constricts Rathke's Pouch. (C) Further development pinches off Rathke's pouch from oral cavity. (D) Rathke's Cleft components develop into the pars distalis, pars tuberalis, and possibly the pars intermedia. Infundibular process develops into infundibular stalk and pars nervosa (From Tindall, Barrow, 1986).




Fig (2) "A" Cross section of a human embryo (3.5 weeks) through the first Cervical somite. "B" Cross Section of a human embryo (5.5 weeks) in the region of the diencephalon. "C" Midsagittal Section of the hypothalamus of a human embryo (11 weeks).

stomedium, and grows cranially toward the neural tube to form the craniopharyngeal duct. The proximal portion of this duct is obliterated by the twelfth week of gestation and loses its connection with the oral cavity. Proliferation of the distal anterior wall of Rathk's pouch forms the pars distalis which makes up most of adult adenohypophysis. The posterior wall of Rathk's pouch, becomes the intermediate lobe, which is largely vestigial in adult humans. A thin layer of anterior pituitary cells the pars tuberalis, surrounds the lower end of pituitary stalk, and extends a short distance above the diaphragma sellae.

The posterior pituitary is formed early in embryogenic life from a down pouching of the diencephalon in the floor of the third ventricle, the upper portion fuses to become the pituitary stalk, and distal end enlarges to become the neurohypophysis (Tindall and Barrow, 1990).

Residual cells of craniopharyngeal duct persist in the posterior lobe of the pituitary, the hypophyseal stalk, and the basisphenoid. These are generally thought to be the origin of the tumour (craniopharyngeoma). Superior pharynx in infants, and adults almost always reveals a pharyngeal hypophysis at the buccal end of craniopharyngeal duct, it is composed mainly of

Review of Literature